BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab)

2 years ago

– BBP-398, an investigational SHP2 inhibitor, is a potentially best-in-class therapy for use in combination approaches, which is shown by…

BioStem Technologies Commends OIG’s Recommendation for CMS to Address ASP Reporting Requirements for Skin Substitute Products

2 years ago

POMPANO BEACH, FLORIDA., March 23, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies (“BioStem” or the “Company”) (OTCQB: BSEM), a leading provider…

Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update

2 years ago

- Completed enrollment of CT1812 Phase 2 SEQUEL study for mild-to-moderate Alzheimer's disease - Received FDA clearance for Phase 2…

Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors

2 years ago

BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel…

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

2 years ago

SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed…

Psyence Group Announces Cantheon Capital Private Placement

2 years ago

VANCOUVER, British Columbia, March 23, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc (CSE:PSYG | OTCQB: PSYGF), a life science biotechnology…

Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023

2 years ago

WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage…

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

2 years ago

– Initial first-in-human clinical data for IL-2 INDUKINE WTX-124 monotherapy expected in 4Q 2023 from Phase 1/1b clinical trial in…

Journey Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023

2 years ago

Company to host conference call to discuss financial results and provide a corporate update on March 29, 2023 at 4:30…

Children’s Hospital Association Selects Progyny as Exclusive Partner for Fertility and Family Building Benefits

2 years ago

As the vendor of choice, Progyny’s comprehensive benefit with proven clinical outcomes will be recommended to the more than 220…